A CD47 antibody with minimized erythrocyte and thrombocyte toxicities
These findings suggest that 1B2-10 demonstrates a favorable efficacy and safety profile, indicating great therapeutic potential for cancer. Based on these studies, 1B2-10 has been renamed as DS003 and is currently advancing through Phase I clinical trials in China to further evaluate its safety profile and preliminary efficacy in human subjects.
Authors
- Guo‐Jian Liu (ORCID: https://orcid.org/0000-0002-6012-6321)
- Chunhe Wang (ORCID: https://orcid.org/0000-0002-9598-8968)
- Xiaojia Chen (ORCID: https://orcid.org/0000-0002-8188-5124)
- Xiaofan Jiang (ORCID: https://orcid.org/0000-0001-5507-083X)
- Xiaodong Dai (ORCID: https://orcid.org/0000-0002-0937-4143)
- Huanhuan Li
- Kaifeng He
- Yaru Wang (ORCID: https://orcid.org/0000-0002-4510-4335)
- Yili Chen (ORCID: https://orcid.org/0000-0002-4404-369X)
- Jie Tan (ORCID: https://orcid.org/0009-0003-6535-2779)
- Jianqiang Zhu (ORCID: https://orcid.org/0009-0000-2117-9183)
- Alison Pan
- Min Pei (ORCID: https://orcid.org/0009-0000-4481-0724)
- Chiou‐Chung Yuan
Institutions
- Nanjing University of Chinese Medicine (CN)
- Jinan University (CN)
- ShanghaiTech University (CN)
- Shanghai CASB Biotechnology (China) (CN)
- Shanghai Institute of Materia Medica (CN)
- Zhongshan Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fonc.2025.1686180
- Citations
- 1
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- National Natural Science Foundation of China